These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31381810)

  • 1. The interaction between RUNX2 and core binding factor beta as a potential therapeutic target in canine osteosarcoma.
    Alegre F; Ormonde AR; Godinez DR; Illendula A; Bushweller JH; Wittenburg LA
    Vet Comp Oncol; 2020 Mar; 18(1):52-63. PubMed ID: 31381810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of copper chaperones sensitizes human and canine osteosarcoma cells to carboplatin chemotherapy.
    Inkol JM; Poon AC; Mutsaers AJ
    Vet Comp Oncol; 2020 Dec; 18(4):559-569. PubMed ID: 32060984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired cell cycle regulation of the osteoblast-related heterodimeric transcription factor Runx2-Cbfbeta in osteosarcoma cells.
    San Martin IA; Varela N; Gaete M; Villegas K; Osorio M; Tapia JC; Antonelli M; Mancilla EE; Pereira BP; Nathan SS; Lian JB; Stein JL; Stein GS; van Wijnen AJ; Galindo M
    J Cell Physiol; 2009 Dec; 221(3):560-71. PubMed ID: 19739101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro.
    McMahon MB; Bear MD; Kulp SK; Pennell ML; London CA
    Am J Vet Res; 2010 Jul; 71(7):799-808. PubMed ID: 20594083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines.
    Couto JI; Bear MD; Lin J; Pennel M; Kulp SK; Kisseberth WC; London CA
    BMC Vet Res; 2012 Dec; 8():244. PubMed ID: 23244668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological activity of dihydroartemisinin in canine osteosarcoma cell lines.
    Hosoya K; Murahari S; Laio A; London CA; Couto CG; Kisseberth WC
    Am J Vet Res; 2008 Apr; 69(4):519-26. PubMed ID: 18380584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma.
    Patatsos K; Shekhar TM; Hawkins CJ
    Vet Comp Oncol; 2018 Dec; 16(4):544-553. PubMed ID: 29998615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YM155 enhances the cytotoxic activity of etoposide against canine osteosarcoma cells.
    Ong SM; Saeki K; Kok MK; Nakagawa T; Nishimura R
    J Vet Med Sci; 2019 Aug; 81(8):1182-1190. PubMed ID: 31308291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro.
    Marley K; Helfand SC; Edris WA; Mata JE; Gitelman AI; Medlock J; Séguin B
    BMC Vet Res; 2013 Jan; 9():15. PubMed ID: 23331343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of sulforaphane on canine osteosarcoma proliferation and invasion.
    Rizzo VL; Levine CB; Wakshlag JJ
    Vet Comp Oncol; 2017 Sep; 15(3):718-730. PubMed ID: 27045198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of lycopene on proliferation and death of canine osteosarcoma cells.
    Wakshlag JJ; Balkman CE
    Am J Vet Res; 2010 Nov; 71(11):1362-70. PubMed ID: 21034328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of anti-proliferative kinase inhibitors as potential therapeutic agents to treat canine osteosarcoma.
    Mauchle U; Selvarajah GT; Mol JA; Kirpensteijn J; Verheije MH
    Vet J; 2015 Aug; 205(2):281-7. PubMed ID: 25190293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the potassium-sparing diuretic amiloride on chemotherapy response in canine osteosarcoma cells.
    Poon AC; Inkol JM; Luu AK; Mutsaers AJ
    J Vet Intern Med; 2019 Mar; 33(2):800-811. PubMed ID: 30556178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs.
    Royals SR; Farese JP; Milner RJ; Lee-Ambrose L; van Gilder J
    Am J Vet Res; 2005 Nov; 66(11):1961-7. PubMed ID: 16334957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melarsomine suppresses canine osteosarcoma cell survival via inhibition of Hedgehog-GLI signaling.
    Nam A; Kim T; Li Q; Rebhun RB; Youn HY; Seo KW
    J Vet Med Sci; 2019 Dec; 81(12):1722-1729. PubMed ID: 31645504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild-type p53.
    York D; Withers SS; Watson KD; Seo KW; Rebhun RB
    Vet Comp Oncol; 2017 Sep; 15(3):1087-1100. PubMed ID: 27333821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 17-AAG and Apoptosis, Autophagy, and Mitophagy in Canine Osteosarcoma Cell Lines.
    Massimini M; Palmieri C; De Maria R; Romanucci M; Malatesta D; De Martinis M; Maniscalco L; Ciccarelli A; Ginaldi L; Buracco P; Bongiovanni L; Della Salda L
    Vet Pathol; 2017 May; 54(3):405-412. PubMed ID: 28438108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of etoposide alone and in combination with piroxicam on canine osteosarcoma cell lines.
    Ong SM; Saeki K; Tanaka Y; Nishimura R; Nakagawa T
    Vet J; 2016 Dec; 218():51-59. PubMed ID: 27938709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of VEGF by tepoxalin does not lead to increased tumour growth in a canine osteosarcoma xenograft.
    Sottnik JL; Hansen RJ; Gustafson DL; Dow SW; Thamm DH
    Vet Comp Oncol; 2011 Jun; 9(2):118-30. PubMed ID: 21569197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial.
    Skorupski KA; Uhl JM; Szivek A; Allstadt Frazier SD; Rebhun RB; Rodriguez CO
    Vet Comp Oncol; 2016 Mar; 14(1):81-7. PubMed ID: 24118677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.